Maanshan Fengyuan Pharmaceutical Co., Ltd.
Published:
2018-08-07
Source:
Author:
Maanshan Fengyuan Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Anhui Fengyuan Pharmaceutical Co., Ltd. It was established in June 2008 on the basis of the original "Anhui Fengyuan Pharmaceutical Co., Ltd. Ma'anshan Pharmaceutical Factory". With a capital of 145.5 million yuan, its predecessor was Maanshan Biochemical Pharmaceutical Factory, which was founded in 1970 and mainly produces biochemical drugs. In 2000, Maanshan Biochemical Pharmaceutical Factory participated in Fengyuan Pharmaceutical Co., Ltd. and was listed on the Shenzhen Stock Exchange. In February 2006, due to the needs of urban planning and company development, it was relocated to the Economic and Technological Development Zone, covering an area of 145 mu.
The company currently has 7 GMP production lines, and has three dosage forms of freeze-dried powder injection, small volume injection and API. The products cover the fields of digestive system, gynecological drugs, hormone drugs, antibacterial drugs, etc., including acetic acid for a class of new drugs for injection Alanorelin, Class II New Drug Ibutilide Fumarate Injection, Class IV New Drug Gonarelin for Injection, Class Five New Drug Dexamethasone Sodium Phosphate for Injection and Vitamin B6 for Injection, and Coenzyme A for Injection of Biochemical Products , oxytocin injection and other 112 approvals.
Maanshan Fengyuan Pharmaceutical Co., Ltd. invested 101 million yuan in 2013 to build three non-terminally sterilized injection production lines. The production lines meet the new GMP certification requirements of the State Food and Drug Administration. The annual production capacity is 100 million bottles of non-hormone freeze-dried powder injections, 50 million bottles of hormone-based freeze-dried powder injections, and 150 million small-volume injections.
In March 2016, Maanshan Fengyuan Pharmaceutical Co., Ltd. invested 100 million yuan again to build a production workshop with an annual output of 50 million cartridges for water injection, which is used to produce oral local anesthetic compound articaine hydrochloride injection. At present, similar products listed in the United States, Europe, Canada and other countries are packaged in cartridges. The new production line of our company will fill the blank of the cartridge-free product in the field of domestic anesthetic injections, and will also be able to meet the extensive demand for cartridge anesthetics due to the rapid development of domestic comfortable oral treatment.
Maanshan Fengyuan Pharmaceutical Co., Ltd. currently has 240 employees, of which more than 38% are professional and technical personnel. At present, the company's total assets are 600 million yuan. In 2018, it achieved sales revenue of 404.6 million yuan and tax payment of 53.61 million yuan; in 2019, it achieved sales revenue of 442.5 million yuan and tax payment of 41.46 million yuan; in 2020, the annual sales revenue was 373 million yuan and tax payment was 45.1 million yuan. ;2021 annual sales revenue of 432 million yuan and tax payment of 24 million yuan
Maanshan Fengyuan Pharmaceutical Co., Ltd. has always attached importance to technological innovation, actively introduced high-tech equipment and technology at home and abroad, and established a complete quality management and monitoring system. The company has 20 product invention patents and 14 high-tech products. In 2008, 2011, 2014, 2017 and 2020, the company was rated as a "high-tech enterprise" for five consecutive times. In 2014, he won a scientific and technological research achievement in Anhui Province, and in 2018, he won the third prize of Anhui Province Science and Technology Award.
Relying on superior production conditions, strong research and development strength, high-quality after-sales service, and perfect quality assurance, the company has laid a foundation for the development of the enterprise.
Related Information
2022-06-30

2022-06-30

2022-06-30
